Sue-Hwa Lin, Ph.D.

Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Professor, Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Member of Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

The work in our lab focuses on the identification of proteins involved in the metastasis of prostate cancer cells to bone and the progression of prostate cancer in bone. Prostate cancer has a propensity to metastasize to bone and induce blastic bone lesions. Bi-directional interactions between prostate cancer cells and osteoblasts likely play important roles in the progression of prostate cancer in bone. We have used protein fractionation and proteomics approaches to identify, in bone marrow samples from prostate cancer patients, factors that may play significant roles in the progression of prostate cancer cells in bone. Several factors have been identified as potential regulators of prostate cancer bone metastasis, and their functional roles in prostate cancer bone metastasis are being investigated. We are also studying adhesion molecules that mediate the metastasis of prostate cancer cells to bone. Because these adhesion molecules likely provide a link between the metastatic prostate cancer cells and the bone, our studies may lead to the development of these adhesion molecules as markers for detecting circulating prostate cancer cells that can potentially colonize in bone. In addition, these studies may lead to new strategies for preventing prostate cancer metastasis to bone.

Education & Training

Degree-Granting Education

1984	Brown University, Providence, Rhode Island, US, Biology and Medicine, Ph.D
1979	National Taiwan University, Taipei, Taiwan, CN, Biochemical Sciences, M.S
1977	National Taiwan University, Taipei, Taiwan, CN, Pharmaceutical Sciences, B.S

Postgraduate Training

1983-1988

Post-Doctoral Fellow, Department of Biochemistry and Molecular Biology, Harvard University, Cambridge, MA

Experience & Service

Faculty Academic Appointments

Co-director, GSBS Molecular Pathology Program, Houston, TX, 2011 - 2013

Ashbel Smith Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2006

Associate Professor, Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1995 - 2000

Instructor, Protein Purification and Characterization, Spring Course, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1994 - 2018

Associate Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1994 - 2000

Assistant Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1988 - 1994

Board of Tutors, Board of Tutors in Biomedical Sciences, Harvard University, Cambridge, MA, 1986 - 1988

Research Associate, Professor Guido Guidotti's Laboratory, Harvard University, Cambridge, MA, 1983 - 1988

Research Assistant, Brown University, Providence, RI, 1982 - 1983

Lecturer, Department of Biochemistry, Brown University, Providence, RI, 1981 - 1982

Teaching Assistant, Department of General Biochemistry, Brown University, Providence, RI, 1980 - 1981

Teaching Assistant, Department of General Biology and Biochemistry, Brown University, Providence, RI, 1979 - 1980

Administrative Appointments/Responsibilities

Deputy Chair, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2012

Intramural Institutional Committee Activities

Member, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2024

Member, Promotion and Tenure Committee Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Institutional Committee, Translational Molecular Pathology Training Program, T32 Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2022

Extramural Institutional Committee Activities

Program Advisor, Bone Disease Program of Texas, The University of Texas MD Anderson Cancer Center, 2016 - 2019

Member, Translational Molecular Pathology Training Program Oversight Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Member, ACS-IRG Review Committee, The University of Texas MD Anderson Cancer Center, 2011

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2009 - 2012

Member, Search Committee, Cardiology Faculty, The University of Texas MD Anderson Cancer Center, 2008 - 2011

Member, Faculty Compensation Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Member, Search Committee, Cancer Biology Chairman, The University of Texas MD Anderson Cancer Center, 2007

Member, Faculty Health Committee, The University of Texas MD Anderson Cancer Center, 2004 - 2005

Member, Education Subcommittee for Education Achievement Award, The University of Texas MD Anderson Cancer Center, 2004

Member, Conflict of Interest Committee (COIC), The University of Texas MD Anderson Cancer Center, 2003 - 2006

Member, Conflict Management Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2006

Member, Committee for Alfred G. Knudson Outstanding Dissertation Award, The University of Texas MD Anderson Cancer Center, 2003 - 2004

Member, Committee for Basic Science Achievement Award, The University of Texas MD Anderson Cancer Center, 2003

Director, Career Development Award, Prostate SPORE program, The University of Texas MD Anderson Cancer Center, 2001 - 2013

Member, Steering Committee of the Keck Center for Cancer Gene Therapy, The University of Texas MD Anderson Cancer Center, 2001 - 2004

Member, Study Section Review Committee for Basic Research Projects under the Institutional Research Grants Program, The University of Texas MD Anderson Cancer Center, 2001 - 2004

Member, Faculty Appeals Panel Representatives, The University of Texas MD Anderson Cancer Center, 2000 - Present

Member, Search Committee for Molecular and Cellular Oncology Chairman, The University of Texas MD Anderson Cancer Center, 2000 - Present

Alternate Representative, Executive Committee of the Science Faculty, The University of Texas MD Anderson Cancer Center, 2000 - Present

Member, Division of Pathology and Laboratory Medicine Steering Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2001

Member, Search Committee for Research Trust Scholars of the MDACC, The University of Texas MD Anderson Cancer Center, 2000 - 2001

Member, Subcommittee for Faculty Achievement Awards, The University of Texas MD Anderson Cancer Center, 1998 - Present

Member, Pathology Program Admission Committee, The University of Texas MD Anderson Cancer Center, 1997 - Present

Member, Search Committee, Biochemistry and Molecular Biology Chairman, The University of Texas MD Anderson Cancer Center, 1997 - Present

Member, Search Committee, Translational Molecular Pathology Faculty, The University of Texas MD Anderson Cancer Center, 1990 - Present

Editorial Activities

Service on Editorial Board, Tumor and Microenvironment, 2015

Executive Editor, Protein Expression and Purification, 2013 - 2016

Service on Editorial Board, Biomedical Research International, 2010 - 2014

Service on Editorial Board, Journal of Biomedicine and Biotechnology, 2009 - 2010

Service on Editorial Board, Cancer Management and Research, 2008 - Present

Service on Editorial Board, Protein Expression and Purification, 2001 - 2013

Honors & Awards

2017	Faculty Honoree Award, Research Excellence
2004 - 2005	Prostate Cancer Foundation Research Award
1998	Association for the Cure of Cancer of the Prostate (CaP CURE) Research Award
1998	The Julie and Ben Rogers Award for Excellence Finalist
1986 - 1988	Medical Foundation Postdoctoral Fellowship

Professional Memberships

American Society for Biochemistry and Molecular Biology

1991 - Present

The New York Academy of Sciences

1990 - 1992

Society for Chinese Bioscientist in America

1989 - Present

American Association for the Advancement of Science

1986 - Present

Selected Presentations & Talks

National Presentations

2009. Why do prostate cancer cells go to bone?. Conference. Why do prostate cancer cells go to bone?. Springfield, IL, US.
2003. CEACAM1, a multifunctional Ig-like protein with potent tumor suppressor activity. Conference. Annual Meeting of The American Society for Investigative Pathology, US.
2002. Antitumor effects of 16-kDa Prolactin. Conference. 84th Annual Meeting of The Endocrine Society, "Hormones, Immunity and Health" section of ENDO 2002, US.
2002. Development and Application of Therapies in Genitourinary Malignancies. Conference. The Ninth Genitourinary Oncology Conference and Melvin Samuels Lectureship. Houston, TX, US.
1999. The Clinical and Laboratory Development of New Therapy Targets for the Treatment of Prostate Cancer. Conference. The Seventh Annual Genitourinary Oncology Conference. Houston, TX, US.
1997. Title not provided. Conference. Fifth Annual Radiation Workshop at Round Top. Round Top, TX, US.
1997. Advances in the Biology and Therapy of Prostate Cancer. Conference. The Fifth Annual Genitourinary Oncology Conference. Houston, TX, US.
1996. 7th Prouts Neck Meeting on Prostate Cancer: Biology and treatment of prostate cancer metastasis. Conference. 7th Prouts Neck Meeting on Prostate Cancer: Biology and treatment of prostate cancer metastasis. Prouts Neck, ME, US.
1996. Cell Growth Suppressors/Regulators: Implications for Cancer Therapy. Conference. Eighth Annual Symposium of the New England Section of the American Association for Cancer Research, US.
1996. Clinical Advances in the Treatment of Genitourinary Tumors. Conference. The Fourth Annual Genitourinary Oncology Conference. Houston, TX, US.
1995. Recent Advances in Antibody Productions by Molecular Cloning and Recombinant Technology. Conference. Society for Basic Urologic Research. Las Vegas, NV, US.
1994. Protein Purification and Characterization. Conference. Cold Spring Harbor Laboratory. Cold Spring Harbor, NY, US.
1989. The Biological Actions of Extracellular ATP. Conference. New York Academy of Science (sponsor), US.

International Presentations

1996. 7th International CEA/PSG Workshop. Conference. 7th International CEA/PSG Workshop. Duarte, US.
1995. Confence on Cell Adhesion Molecules and Cell-Matrix Receptors in Vertebrate Tissues. Conference. 1995 Nobel Conference, SE.

Formal Peers

2018. Stromal cell lineage plasticity in prostate cancer-induced aberrant bone formation. Invited, TX, US.
2018. Development of Novel Therapies targeting prostate cancer-induced aberrant bone formation. Invited, TX, US.
2018. Prostate cancer bone metastasis. Invited. Cold Spring Harbor, NY, US.
2018. Epithelial-to-osteoblast conversion in prostate cancer bone metastasis. Invited, TX, US.
2017. Prostate cancer bone metastasis. Invited. Taipei City, Taiwan, TW.
2017. Prostate cancer bone metastasis. Invited, US.
2017. Prostate cancer bone metastasis. Invited. Cold Spring Harbor, NY, US.
2016. Prostate cancer bone metastasis. Invited, US.
2016. Prostate cancer bone metastasis. Invited, TX, US.
2016. Approaches to Preventing Prostate Bone Metastasis. Invited, GA, US.
2016. Targeting tumor microenvironment-induced therapy resistance in prostate cancer bone metastasis. Invited, TX, US.
2016. Prostate cancer bone metastasis secretome. Invited. Cold Spring Harbor, NY, US.
2015. Strategies for preventing prostate cancer bone metastasis. Invited. Taipei City, Taiwan, TW.
2014. Prostate cancer bone metastasis secretome. Invited. Cold Spring Harbor, NY, US.
2013. Secretome analysis of prostate cancer bone metastasis. Invited. Cold Spring Harbor, NY, US.
2013. Osteogenesis in prostate cancer bone metastasis. Invited. Houston, TX, US.
2012. Prostate cancer bone metastasis secretome. Invited. Cold Spring Harbor, NY, US.
2011. New targets for prevention and diagnosis of prostate cancer bone metastasis. Invited. Houston, TX, US.
2011. New targets for prevention and diagnosis of prostate cancer bone metastasis. Invited. Houston, TX, US.
2011. Cell adhesion molecules and prostate cancer metastasis. Invited. Cold Spring Harbor, NY, US.
2011. Tumor microenvironment in prostate cancer metastasis. Invited. Houston, TX, US.
2011. Tumor microenvironment in prostate cancer metastasis. Invited. Houston, TX, US.
2010. Why do prostate cancer cells go to bone?. Invited, TX, US.
2009. Why do prostate cancer cells to to bone?. Invited. Cold Spring Harbor, NY, US.
2008. Why do prostate cancer cells go to bone?. Invited. Rochester, NY, US.
2008. Adhesion molecules and osteogenesis in prostate cancer metastasis to bone. Invited. Cold Spring Harbor, NY, US.
2008. Why do prostate cancer cells go to bone?. Invited. Houston, TX, US.
2007. Adhesion molecules and osteogenesis in prostate cancer metastasis to bone. Invited. Houston, TX, US.
2007. Spread of prostate cancer to bone. Invited. Taipei, Taiwan, TW.
2007. Bone microenvironment and androgen status regulate nuclear localization of ErbB3. Invited, US.
2007. Adhesion molecules in prostate cancer metastasis to bone. Invited. Houston, TX, US.
2007. Adhesion molecules and osteogenesis in prostate cancer metastasis to bone. Invited. Houston, TX, US.
2007. Adhesion molecules and osteogenesis in prostate cancer metastasis to bone. Invited. Cold Spring Harbor, NY, US.
2006. Osteoblast in prostate cancer metastasis to bone. Invited. Cold Spring Harbor, NY, US.
2005. Osteoblast regulatory activity in patients with metastatic prostate cancer. Invited. Houston, TX, US.
2005. The bone marrow proteome as a discovery platform to understand prostate cancer progression. Invited. Cold Spring Harbor, NY, US.
2005. The bone marrow proteome as a discovery platform to understand prostate cancer progression. Invited. Houston, TX, US.
2005. Osteoblast stimulating factors in prostate cancer bone metastasis. Invited, US.
2004. Factors involved in prostate cancer bone metastasis. Invited. Washington, US.
2004. Novel approach to understanding prostate cancer bone metastasis. Invited. Cold Spring Harbor, NY, US.
2004. Novel approach to understanding prostate cancer bone metastasis. Invited, US.
2003. Identification of bone epithelium interacting factors from bone marrow of prostate cancer patients with bone metastasis. Invited. San Antonio, TX, US.
2003. Novel approach to understanding prostate cancer bone metastasis. Invited. Houston, TX, US.
2003. CEACAM1 cell adhesion molecule: new functions for an old molecule. Invited, US.
2003. Prostate Cancer Bone Metastasis. Invited. Cold Spring Harbor, NY, US.
2003. Bone-epithelial interaction factors in prostate cancer bone metastasis. Invited. Houston, TX, US.
2003. Prostate Cancer Bone Metastasis. Invited, PR.
2002. Identification of genes differentially expressed in prostate cancer bone metastasis. Invited. San Francisco, CA, US.
2002. 16-kDa fragment of prolactin as an antiangiogenic agent. Invited. Houston, TX, US.
2002. Antitumor activity of 16-kDa prolactin. Invited. Cold Spring Harbor, NY, US.
2002. Strategies for the identification of bone-metastasis related factors in advanced prostate cancer. Invited. Houston, TX, US.
2001. Identification of bone-metastasis related factors in advanced prostate cancer. Invited. Houston, TX, US.
2001. Isolation and identification of bone-response factors from bone marrow of patients with prostate cancer bone metastasis. Invited. Cold Spring Harbor, NY, US.
2001. Regulation of angiogenesis by C-CAM1 tumor suppressor. Invited. Houston, TX, US.
2001. Regulation of angiogenesis by C-CAM1 tumor suppressor. Invited. Houston, TX, US.
2001. Regulation of angiogenesis by C-CAM1 tumor suppressor. Invited. Houston, TX, US.
2000. C-CAM: A novel tumor suppressor with antiangiogenic activity. Invited. Houston, TX, US.
2000. C-CAM and Angiogenesis. Invited. Houston, TX, US.
2000. Molecular Biology of Prostate Cancer: The 20th Annual Meeting. Invited. Philadelphia, PA, US.
2000. Cell Surface Markers. Invited. Houston, TX, US.
2000. Regulation of angiogenesis by C-CAM tumor suppressor in prostate cancer. Invited. Madison, WI, US.
2000. C-CAM1: A novel tumor suppressor with anti-angiogenic activity. Invited. Cold Spring Harbor, NY, US.
2000. C-CAM1: A novel tumor suppressor with anti-angiogenic activity. Invited, OH, US.
1999. C-CAM1: A novel tumor suppressor with anti-angiogenic activity. Invited, US.
1999. Enhanced suppression of prostate tumor growth by combination of C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Invited, US.
1999. C-CAM1: A novel tumor suppressor with antiangiogenesis activity. Invited, US.
1999. C-CAM: A novel tumor suppressor with antiangiogenic activity. Invited. Houston, TX, US.
1999. C-CAM: A novel tumor suppressor with antiangiogenesis activity. Protein Purification and Characterization Course. Invited. Cold Spring Harbor, NY, US.
1998. C-CAM: A novel tumor suppressor with anti-angiogenesis activity. Invited, US.
1998. Role of Cell Adhesion Molecule (C-CAM) in Prostate Cancer. Invited. Cold Spring Harbor, NY, US.
1997. Effects of a cell adhesion molecule CD66a (Human C-CAM1) on the malignant phenotype of human prostate cancer cells. Invited. Estes Park, CO, US.
1997. Cell adhesion molecule (C-CAM) as therapy target: mechanism and application. Invited. Houston, TX, US.
1997. Mechanism of C-CAM1-mediated tumor suppression. Invited. Houston, TX, US.
1997. Role of C-CAM in prostate cancer progression and its application in prostate cancer therapy. Invited, TW.
1997. Application of C-CAM tumor suppressor in prostate cancer therapy. Invited, US.
1997. Role of a cell adhesion molecule (C-CAM) in prostate cancer. Invited. Houston, TX, US.
1997. Application of C-CAM tumor suppressor in prostate cancer therapy. Invited. Houston, TX, US.
1997. Role of a cell adhesion molecule (C-CAM) in prostate cancer. Invited. Cold Spring Harbor, NY, US.
1997. Role of a cell adhesion molecule (C-CAM) in prostate cancer. Invited. Nashville, TN, US.
1997. Role of C-CAM in prostate cancer progression and its application in gene therapy. Invited, US.
1997. Application of C-CAM Tumor Suppressor in Prostate Cancer Therapy. Invited, US.
1997. Application of C-CAM tumor suppressor in prostate cancer therapy. Invited. Houston, TX, US.
1996. Role of C-CAM as a tumor suppressor in prostate cancer. Invited. Houston, TX, US.
1996. Role of C-CAM as a tumor suppressor in prostate cancer: from basic research to clinical application. Invited. Houston, VA, US.
1996. The role of C-CAM cell adhesion molecule in prostate cancer progression. Invited. Houston, TX, US.
1996. Role of C-CAM as a tumor suppressor in prostate cancer. Invited. Houston, TX, US.
1996. Use of C-CAM adenovirus in prostate cancer gene therapy. Invited. Houston, TX, US.
1996. Role of C-CAM in prostate cancer progression. Invited. Houston, TX, US.
1995. C-CAM as a tumor suppressor in prostate cancer. Invited. Charlesville, VA, US.
1995. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy. Invited. Montreal, CA.
1994. Role of a cell adhesion molecule in prostate cancer progression. Invited. Houston, TX, US.
1994. C-CAM: A novel tumor suppressor in prostatic cancer progression. Invited. Freiburg, DE.
1994. Suppression of tumorigenicity of human prostate cancer cells by expression of an androgen-regulated cell adhesion molecule, C-CAM. Invited. Houston, TX, US.
1994. C-CAM: a novel tumor suppressor in prostatic cancer progression. Invited. Houston, TX, US.
1993. C-CAM: a cell adhesion molecule and tumor suppressor. Invited. Houston, TX, US.
1993. Structure, function and regulation of C-CAM: a cell adhesion molecule. Invited. Houston, TX, US.
1993. C-CAM: a cell adhesion molecule and tumor suppressor. Invited. Houston, TX, US.
1993. Structure, function and regulation of C-CAM: An epithelial cell adhesion molecule. Invited, US.
1993. Structure, function and regulation of C-CAM: An hepatocyte cell adhesion molecule. Invited, US.
1993. Structure, function and regulation of C-CAM: An epithelial cell adhesion molecule. Invited, US.
1993. Structure, function and regulation of C-CAM: An epithelial cell adhesion molecule. Invited, US.
1993. Structure, function and regulation of C-CAM: An epithelial cell adhesion molecule. Invited, US.
1992. Structure, function and regulation of cell-CAM105: A hepatocyte cell adhesion molecule. Invited, US.
1991. A newly identified brush border protein: A cell adhesion molecule and an ATPase. Invited. Houston, TX, US.
1991. Cell-CAM 105: A CEA-like cell adhesion molecule with ATPase activity. Invited. Houston, TX, US.
1991. Rat liver ecto-ATPases: purification, cloning, structure and function. Invited, US.
1991. Studies of liver ecto-ATPases: A cell adhesion molecule of CEA family. Invited, US.
1990. Studies of liver ecto-ATPases: A cell adhesion molecule of CEA family. Division of Laboratory Medicine, Lecture in "Topics in Laboratory Medicine Conference". Invited. Houston, TX, US.
1990. Plasma membrane ecto-ATPase: Characterization, purification, cloning and functions. Invited, US.
1989. Multiple functions of plasma membrane ecto-ATPases. Invited, US.
1989. Liver plasma membrane ecto-ATPase: Localization and cloning. Invited. Houston, TX, US.
1989. Rat hepatocyte ecto-ATPase: Localization, properties and cloning. Invited. San Diego, CA, US.
1989. Function and localization of liver plasma membrane ecto-ATPase. Invited. Houston, TX, US.

Less

Grant & Contract Support

Date:	2025 - 2028
Title:	Targeting ACOD1 in PMN-MDSCs as a Novel Approach to Overcome Immunotherapy Resistance in Bone Metastases of Prostate Cancer
Funding Source:	Cancer Prevention Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP260044

Date:	2025 - 2028
Title:	Approaches to Overcoming T Cell Insufficiency inThe Bone-Tumor Microenvironment for Bone Metastatic Prostate Cancer Therapies
Funding Source:	Cancer Prevention Research Institute of Texas (CPRIT)
Role:	PI

Date:	2025 - 2030
Title:	Comprehensive Clinical and Co-Clinical Characterization of Prostate Cancers Transitioning from Treatable to Lethal Phenotypes to Inform Individualized Treatment Strategy
Funding Source:	Prostate Cancer Foundation
Role:	PI
ID:	2025TACT4985,

Date:	2025 - 2030
Title:	Prostate Cancer-Induced Bone Formation Regulates Immune Microenvironment in Prostate Cancer Bone Metastasis
Funding Source:	National Institute of Health/NCI
Role:	PI
ID:	1R01CA278987

Date:	2023 - 2028
Title:	Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) Program
Funding Source:	National Institute of Health/NCI
Role:	PI
ID:	1 R25 CA265800-01A1

Date:	2023 - 2026
Title:	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP230247

Date:	2022 - 2027
Title:	Cis-Aconitate Decarboxylase (ACOD1) in PMN-MDSC and Prostate Cancer Progression
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R0CA276235

Date:	2022 - 2023
Title:	Targeting prostate tumor-induced bone formation to reverse the immunosuppressive bone-TME and improve the efficacy of immune checkpoint therapies
Funding Source:	MDACC Prostate Cancer Moonshot
Role:	PI

Date:	2022 - 2023
Title:	A novel therapy targeting the immune-suppressive environment of bone metastasis
Funding Source:	MDACC Bridge Funding
Role:	PI

Date:	2020 - 2022
Title:	Targeting the Osteogenic Niche for Preventing Kidney Cancer Bone Metastasis Progression
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	W81XWH-20-10895

Date:	2019 - 2022
Title:	A Novel Therapy Targeting Prostate Cancer-Induced Aberrant Bone Formation
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP190252

Date:	2018 - 2023
Title:	Endothelial-to-Osteoblast Transition in Prostate Cancer Bone Metastasis
Funding Source:	NIH/NCI
Role:	PI
ID:	CA174798-06A1

Date:	2018 - 2019
Title:	UTMDACC Prostate Moonshot Program
Funding Source:	Director of Flagship #3
Role:	Co-Director

Date:	2016 - 2021
Title:	Administration Core
Funding Source:	NIH/NCI
Role:	Co-Director
ID:	CA140388

Date:	2016 - 2022
Title:	Osteocrines in Therapy Resistance of Prostate Cancer Bone Metastasis
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	CA140388, Project 2, UTMDACC SPORE

Date:	2015 - 2017
Title:	BIGH3 inhibition of osteoblasts as a novel mechanism of osteolysis in kidney cancer bone metastasis
Funding Source:	Knowledge Gap Grant
Role:	Collaborator

Date:	2015 - 2018
Title:	Regulation of Dormancy of Metastatic Prostate Cancer Cells by Bone Microenvironment
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP150179

Date:	2015 - 2018
Title:	Mechanisms of De Novo and Acquired Resistance to Therapeutic Treatment of Bone-Metastatic Prostate Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP150282

Date:	2015 - 2017
Title:	de novo Therapy Resistance from Prostate Cancer Metastasis-induced Bone Formation
Funding Source:	Institutional Research Grant
Role:	Collaborator

Date:	2015 - 2017
Title:	Bone Microenvironment on Dormancy of Metastatic Prostate Cancer Cells
Funding Source:	UTMDACC Sister Institution Network Fund
Role:	PI

Date:	2014 - 2015
Title:	Osteocrines in Therapy Resistance of Prostate Cancer Bone Metastasis: Evaluation of Strategies to Overcome Therapy Resistance from Tumor-Educated Bone Microenvironment
Funding Source:	Prostate Cancer Foundation
Role:	PI

Date:	2013 - 2015
Title:	Osteocrines in Therapy Resistance of Prostate Cancer Bone Metastasis
Funding Source:	NIH/NCI
Role:	PI
ID:	CA140388

Date:	2013 - 2018
Title:	Endothelial-to-Osteoblast Transition in Prostate Cancer Bone Metastasis
Funding Source:	NIH/NCI
Role:	PI
ID:	CA174798

Date:	2013 - 2025
Title:	Endothelial-to-Osteoblast Transition in Prostate Cancer Bone Metastasis
Funding Source:	National Institute of Health/NCI
Role:	PI
ID:	5R01 CA174798-10

Date:	2012 - 2015
Title:	Kidney Bone Metastasis
Funding Source:	Department of Orthopaedic Surgery-Institutional Research Fund
Role:	Mentor

Date:	2012 - 2014
Title:	Osteocalcin in Castration-Resistant Prostate Cancer
Funding Source:	Prostate Cancer SPORE Development Research Program
Role:	PI

Date:	2012 - 2015
Title:	Bone Marrow-derived mesenchymal stem cells in prostate cancer-induced bone remodeling
Funding Source:	UTMDACC Sister Institution Network Fund
Role:	PI

Date:	2011 - 2013
Title:	Prostate Cancer Bone Metastasis Secretome
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP110327

Date:	2010 - 2013
Title:	Clinical Applications for Cadherin-11 in Prostate Cancer Bone Metastasis
Funding Source:	Prostate Cancer Foundation
Role:	Mentor

Date:	2010 - 2014
Title:	Cadherin-11 as a target for bone metastasis prevention
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	W81XWH-10-1-0074

Date:	2010 - 2012
Title:	Prostate Cancer Foundation Clinical Research Consortium: Individualized Microenvironment Targeted Therapy for Prostate Cancer Bone Metastases: Rapid Evaluation of Multiple Therapeutic Agents
Funding Source:	Prostate Cancer Foundation
Role:	Co-PI

Date:	2010 - 2011
Title:	Cadherin-11 in Circulating Tumor Cells for Prediction and Prevention of Prostate Cancer Bone Metastasis
Funding Source:	NIH/NCI
Role:	PI
ID:	CA140388 (PP-DRP3)

Date:	2009 - 2014
Title:	Career Development Award Component, Special Program of Research Excellence (SPORE) in Prostate Cancer
Funding Source:	NIH/NCI
Role:	Director
ID:	CA090270

Date:	2009 - 2011
Title:	Special Program of Research Excellence (SPORE) in Prostate Cancer
Funding Source:	SPORE
Role:	PI

Date:	2009 - 2011
Title:	Circulating Osteoblast Lineage Cells as a New Biomarker in Prostate Cancer Bone Metastasis
Funding Source:	UT MD Anderson Cancer Center
Role:	Co-PI

Date:	2009 - 2013
Title:	RSK2 in Prostate Cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	W81XWH-09-10272 PC080847

Date:	2009 - 2010
Title:	Targeting HDAC3, A Novel Microtubule Regulator in Cancer Therapy
Funding Source:	Dan L. Duncan Cancer Center
Role:	Co-PI

Date:	2008 - 2010
Title:	Skeletal Metastasis in Prostate Cancer
Funding Source:	Robert Wood Johnson Foundation Fellow Grant
Role:	Mentor

Date:	2008 - 2013
Title:	Bone Microenvironment in Prostate Cancer Bone Metastasis
Funding Source:	Prostate Cancer Research Program (MDACC)
Role:	PI

Date:	2007 - 2009
Title:	Osteoblast Cadherin (OB-Cadherin) for the Prediction and Prevention of Bone Metastasis
Funding Source:	Prostate Cancer Foundation
Role:	PI

Date:	2006 - 2011
Title:	Bone Metastasis Factor-1 in Prostate Cancer/Bone Interaction
Funding Source:	NIH/NCI
Role:	PI
ID:	CA111479

Date:	2005 - 2011
Title:	Bone Metastasis Factor-1 in Prostate Cancer/Bone Interaction
Funding Source:	NIH/NCI
Role:	PI
ID:	CA111479

Selected Publications

Peer-Reviewed Articles

Tan T, Wu C, Wang R, Pan BF, Hawke D, Yin F, Su Z, Liu B, Lin SH, Zhang W, Kuang J. Revisiting phosphoregulation of Cdc25C during M-phase induction. iScience 28(1):111603, 2025. e-Pub 2025. PMID: 39834856.
Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci U S A 121(33):e2402903121, 2024. e-Pub 2024. PMID: 39102549.
Pan, T, Liu, F, Hao, X, Wang, S, Wasi, M, Song, J, Lewis, VO, Lin, PP, Moon, BS, Bird, JE, Panaretakis, T, Lin, S, Wu, D, Farach-Carson, MC, Wang, L, Zhang, N, An, Z, Zhang, XH, Satcher, R. BIGH3 mediates apoptosis and gap junction failure in osteocytes during renal cell carcinoma bone metastasis progression. Cancer Letters 596, 2024. e-Pub 2024. PMID: 38849015.
Lin, SC, Yu, G, Corn, P, Damasco, J, Lee, Y, Song, J, Navone, NM, Logothetis, CJ, Melancon, MP, Panaretakis, T, Lin, S. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice. Cancers 16(14), 2024. e-Pub 2024. PMID: 39061241.
Sakellakis, M, Hahn, AW, Ramachandran, S, Zhang, M, Hoang, A, Song, J, Liu, J, Wang, F, Basu, HS, Sheperd, P, Wang, X, Frigo, DE, Lin, S, Panaretakis, T, Zhang, J, Navone, NM, Troncoso, P, Logothetis, CJ, Titus, M. Characterization of prostate cancer adrenal metastases. Prostate Cancer and Prostatic Diseases 26(4):751-758, 2023. e-Pub 2023. PMID: 36100698.
Gentile, E, Hahn, AW, Song, J, Hoang, A, Shepherd, P, Ramachandran, S, Navone, NM, Efstathiou, E, Titus, M, Corn, P, Lin, S, Logothetis, CJ, Panaretakis, T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Research Communications 3(12):2531-2543, 2023. e-Pub 2023. PMID: 37930121.
Vardaki, I, Özcan, SS, Fonseca, P, Lin, S, Logothetis, CJ, Yachnin, J, Ullén, A, Panaretakis, T. Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer. Prostate 83(10):950-961, 2023. e-Pub 2023. PMID: 37074030.
Damasco JA, Yu G, Kumar A, Perez J, Lirag RCM, Whitley EM, Lin SH, Melancon MP. Alendronate conjugate for targeted delivery to bone-forming prostate cancer. Talanta 256:124308, 2023. e-Pub 2023. PMID: 36774896.
Lin SC, Yu G, Lee YC, Song JH, Song X, Zhang J, Panaretakis T, Logothetis CJ, Komatsu Y, Yu-Lee LY, Wang G, Lin SH. Endothelial-to-osteoblast transition in normal mouse bone development. iScience 26(2):105994, 2023. e-Pub 2023. PMID: 36798441.
Tan, T, Wu, C, Liu, B, Pan, BF, Hawke, DH, Su, Z, Liu, S, Zhang, W, Wang, R, Lin, S, Kuang, J. Revisiting the multisite phosphorylation that produces the M-phase supershift of key mitotic regulators. Molecular Biology of the Cell 33(12), 2022. e-Pub 2022. PMID: 35976701.
Yu G, Corn PG, Shen P, Song JH, Lee YC, Lin SC, Pan J, Agarwal SK, Panaretakis T, Pacifici M, Logothetis CJ, Yu-Lee LY, Lin SH. Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. Cancer Res 82(17):3158-3171, 2022. e-Pub 2022. PMID: 35802768.
Lee YC, Lin SC, Yu G, Zhu M, Song JH, Rivera K, Pappin DJ, Logothetis CJ, Panaretakis T, Wang G, Yu-Lee LY, Lin SH. Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene 41(6):757-769, 2022. e-Pub 2022. PMID: 34845375.
Tu SM, Estecio MR, Lin SH, Zacharias NM. Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?. Cancers (Basel) 14(3), 2022. e-Pub 2022. PMID: 35158923.
Zhu M, Peng R, Liang X, Lan Z, Tang M, Hou P, Song JH, Mak CSL, Park J, Zheng SE, Huang A, Ma X, Chen R, Chang Q, Logothetis CJ, Jain AK, Lin SH, Katayama H, Hanash S, Wang G. P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene 40(41):6049-6056, 2021. e-Pub 2021. PMID: 34471235.
Pan T, Lin SC, Lee YC, Yu G, Song JH, Pan J, Titus M, Satcher RL, Panaretakis T, Logothetis C, Yu-Lee LY, Lin SH. Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene 40(27):4592-4603, 2021. e-Pub 2021. PMID: 34127814.
Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone N, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res 27(11):3253-3264, 2021. e-Pub 2021. PMID: 33753455.
Yu G, Shen P, Lee YC, Pan J, Song JH, Pan T, Lin SC, Liang X, Wang G, Panaretakis T, Logothetis CJ, Gallick GE, Yu-Lee LY, Lin SH. Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. iScience 24(4):102388, 2021. e-Pub 2021. PMID: 33981975.
Rojo RD, Perez JVD, Damasco JA, Yu G, Lin SC, Heralde FM, Novone NM, Santos EB, Lin SH, Melancon MP. Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice. Int J Hyperthermia 38(1):650-662, 2021. e-Pub 2021. PMID: 33882773.
Pan T, Martinez M, Hubka KM, Song JH, Lin SC, Yu G, Lee YC, Gallick GE, Tu SM, Harrington DA, Farach-Carson MC, Lin SH, Satcher RL. Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo. Mol Cancer Ther 19(6):1266-1278, 2020. e-Pub 2020. PMID: 32220969.
Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
Mitani Y, Lin SH, Pytynia KB, Ferrarotto R, El-Naggar AK. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Clin Cancer Res 26(5):1175-1184, 2020. e-Pub 2020. PMID: 31772120.
Koinis F, Corn P, Parikh N, Song J, Vardaki I, Mourkioti I, Lin SH, Logothetis C, Panaretakis T, Gallick G. Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers (Basel) 12(1), 2020. e-Pub 2020. PMID: 31963871.
Yu-Lee LY, Lee YC, Pan J, Lin SC, Pan T, Yu G, Hawke DH, Pan BF, Lin SH. Bone secreted factors induce cellular quiescence in prostate cancer cells. Sci Rep 9(1):18635, 2019. e-Pub 2019. PMID: 31819067.
Esposito M, Mondal N, Greco TM, Wei Y, Spadazzi C, Lin SC, Zheng H, Cheung C, Magnani JL, Lin SH, Cristea IM, Sackstein R, Kang Y. Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Nat Cell Biol 21(5):627-639, 2019. e-Pub 2019. PMID: 30988423.
Chahoud J, Zhang M, Pisters LL, Lin SC, Lin SH, Tu SM. Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clin Genitourin Cancer 16(5):325-327, 2018. e-Pub 2018. PMID: 29807831.
Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124(18):3693-3705, 2018. e-Pub 2018. PMID: 30289966.
Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH. Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78(11):2911-2924, 2018. e-Pub 2018. PMID: 29514796.
Yu G, Cheng CJ, Lin SC, Lee YC, Frigo DE, Yu-Lee LY, Gallick GE, Titus MA, Nutt LK, Lin SH. Organelle-Derived Acetyl-CoA Promotes Prostate Cancer Cell Survival, Migration, and Metastasis via Activation of Calmodulin Kinase II. Cancer Res 78(10):2490-2502, 2018. e-Pub 2018. PMID: 29535221.
Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL. BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20(1):32-43, 2018. e-Pub 2018. PMID: 29190493.
Yu KJ, Li JK, Lee YC, Yu G, Lin SC, Pan T, Satcher RL, Titus MA, Yu-Lee LY, Weng WH, Gallick GE, Lin SH. Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget 8(43):74987-75006, 2017. e-Pub 2017. PMID: 29088840.
Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol 80(3):583-589, 2017. e-Pub 2017. PMID: 28730293.
Bilen MA, Pan T, Lee YC, Lin SC, Yu G, Pan J, Hawke D, Pan BF, Vykoukal J, Gray K, Satcher RL, Gallick GE, Yu-Lee LY, Lin SH. Proteomics Profiling of Exosomes from Primary Mouse Osteoblasts under Proliferation versus Mineralization Conditions and Characterization of Their Uptake into Prostate Cancer Cells. J Proteome Res 16(8):2709-2728, 2017. e-Pub 2017. PMID: 28675788.
Lin SC, Lee YC, Yu G, Cheng CJ, Zhou X, Chu K, Murshed M, Le NT, Baseler L, Abe JI, Fujiwara K, deCrombrugghe B, Logothetis CJ, Gallick GE, Yu-Lee LY, Maity SN, Lin SH. Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell 41(5):467-480.e3, 2017. e-Pub 2017. PMID: 28586644.
Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer 15(3):363-370, 2017. e-Pub 2017. PMID: 28216278.
Zeng H, Ortiz A, Shen PF, Cheng CJ, Lee YC, Yu G, Lin SC, Creighton CJ, Yu-Lee LY, Lin SH. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway. Oncotarget 8(6):10145-10160, 2017. e-Pub 2017. PMID: 28052036.
Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget 7(52):86280-86289, 2016. e-Pub 2016. PMID: 27861143.
Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer 122(12):1836-43, 2016. e-Pub 2016. PMID: 27018785.
Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22(1):107-21, 2016. e-Pub 2016. PMID: 26272062.
Chen J, Raju GS, Jogunoori W, Menon V, Majumdar A, Chen JS, Gi YJ, Jeong YS, Phan L, Belkin M, Gu S, Kundra S, Mistry NA, Zhang J, Su X, Li S, Lin SH, Javle M, McMurray JS, Rahlfs TF, Mishra B, White J, Rashid A, Beauchemin N, Weston BR, Shafi MA, Stroehlein JR, Davila M, Akbani R, Weinstein JN, Wu X, Mishra L. Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas. PLoS One 11(4):e0153933, 2016. e-Pub 2016. PMID: 27100181.
Satcher RL, Pan T, Bilen MA, Li X, Lee YC, Ortiz A, Kowalczyk AP, Yu-Lee LY, Lin SH. Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells. J Cell Sci 128(24):4629-41, 2015. e-Pub 2015. PMID: 26519476.
Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res 75(22):4949-59, 2015. e-Pub 2015. PMID: 26530902.
Pan T, Fong EL, Martinez M, Harrington DA, Lin SH, Farach-Carson MC, Satcher RL. Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases. Cancer Lett 365(1):89-95, 2015. e-Pub 2015. PMID: 26004343.
Lee YC, Liu HC, Chuang C, Lin SH. Lectin-magnetic beads for plasma membrane isolation 2015(7):674-8, 2015. e-Pub 2015. PMID: 26134902.
Tu SM, Bilen MA, Lin SH. Radium-223: Optimizing Treatment and Research of Osteoblastic Bone Metastasis. Oncology (Williston Park) 29(7):490-2, 2015. e-Pub 2015. PMID: 26178337.
Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget 6(12):10175-94, 2015. e-Pub 2015. PMID: 25868388.
Jin JK, Tien PC, Cheng CJ, Song JH, Huang C, Lin SH, Gallick GE. Talin1 phosphorylation activates β1 integrins: a novel mechanism to promote prostate cancer bone metastasis. Oncogene 34(14):1811-21, 2015. e-Pub 2015. PMID: 24793790.
Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics 14(3):471-83, 2015. e-Pub 2015. PMID: 25527621.
Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A 112(12):3776-81, 2015. e-Pub 2015. PMID: 25762070.
Ortiz A, Lee YC, Yu G, Liu HC, Lin SC, Bilen MA, Cho H, Yu-Lee LY, Lin SH. Angiomotin is a novel component of cadherin-11/β-catenin/p120 complex and is critical for cadherin-11-mediated cell migration. FASEB J 29(3):1080-91, 2015. e-Pub 2015. PMID: 25466890.
Yu G, Lee YC, Cheng CJ, Wu CF, Song JH, Gallick GE, Yu-Lee LY, Kuang J, Lin SH. RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res 13(2):348-57, 2015. e-Pub 2015. PMID: 25189355.
Sun S, Zhou X, Corvera J, Gallick GE, Lin SH, Kuang J. ALG-2 activates the MVB sorting function of ALIX through relieving its intramolecular interaction. Cell Discov 1:15018, 2015. e-Pub 2015. PMID: 27462417.
Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, Tu SM. Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. Case Rep Oncol Med 2015:471861, 2015. e-Pub 2015. PMID: 25861496.
Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res 20(24):6570-81, 2014. e-Pub 2014. PMID: 25316813.
Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. Can J Urol 21(5):7442-8, 2014. e-Pub 2014. PMID: 25347368.
Satcher RL, Pan T, Cheng CJ, Lee YC, Lin SC, Yu G, Li X, Hoang AG, Tamboli P, Jonasch E, Gallick GE, Lin SH. Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One 9(2):e89880, 2014. e-Pub 2014. PMID: 24587095.
Lee YC, Bilen MA, Yu G, Lin SC, Huang CF, Ortiz A, Cho H, Song JH, Satcher RL, Kuang J, Gallick GE, Yu-Lee LY, Huang W, Lin SH. Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis. Mol Cancer Res 11(11):1401-11, 2013. e-Pub 2013. PMID: 23913163.
McCoy F, Darbandi R, Lee HC, Bharatham K, Moldoveanu T, Grace CR, Dodd K, Lin W, Chen SI, Tangallapally RP, Kurokawa M, Lee RE, Shelat AA, Chen T, Green DR, Harris RA, Lin SH, Fissore RA, Colbran RJ, Nutt LK. Metabolic activation of CaMKII by coenzyme A. Mol Cell 52(3):325-39, 2013. e-Pub 2013. PMID: 24095281.
Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8):849-61, 2013. e-Pub 2013. PMID: 23811619.
Deeraksa A, Pan J, Sha Y, Liu XD, Eissa NT, Lin SH, Yu-Lee LY. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 32(24):2973-83, 2013. e-Pub 2013. PMID: 22890325.
Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, Bornmann WG, Yu-Lee LY, Gallick GE, Zhang W, Lin SH, Kuang J. RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B. Oncogene. e-Pub 2013. PMID: 23708659.
Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH. Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res 11(4):405-17, 2013. e-Pub 2013. PMID: 23339185.
McCoy F, Darbandi R, Chen SI, Eckard L, Dodd K, Jones K, Baucum AJ, Gibbons JA, Lin SH, Colbran RJ, Nutt LK. Metabolic regulation of CaMKII protein and caspases in Xenopus laevis egg extracts. J Biol Chem 288(13):8838-48, 2013. e-Pub 2013. PMID: 23400775.
Chuang C, Pan J, Hawke DH, Lin SH, Yu-Lee LY. NudC deacetylation regulates mitotic progression. PLoS One 8(9):e73841, 2013. e-Pub 2013. PMID: 24069238.
Sung SY, Liao CH, Wu HP, Hsiao WC, Wu IH, Jinpu, Yu, Lin SH, Hsieh CL. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS One 8(8):e71637, 2013. e-Pub 2013. PMID: 23977098.
Fadri-Moskwik M, Weiderhold KN, Deeraksa A, Chuang C, Pan J, Lin SH, Yu-Lee LY. Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells. FASEB J 26(10):4057-67, 2012. e-Pub 2012. PMID: 22751009.
Tu SM, Lin SH. Prostate cancer stem cells. Clin Genitourin Cancer 10(2):69-76, 2012. e-Pub 2012. PMID: 22421313.
Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW, Kobayashi R, Logothetis CJ, Yu-Lee LY, Lin SH. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate 72(3):291-300, 2012. e-Pub 2012. PMID: 21681775.
Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4(1):107-19, 2012. e-Pub 2012. PMID: 22168167.
Y-C L, Gajdusik MS, Josic D, Lin SH. Plasma membrane isolation using immobilized concanavalin a magnetic beads. Methods in Molecular Biology 909:29-41, 2012. e-Pub 2012.
Xie X, Qin J, Lin SH, Tsai SY, Tsai MJ. Nuclear receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) modulates mesenchymal cell commitment and differentiation. Proc Natl Acad Sci U S A 108(36):14843-8, 2011. e-Pub 2011. PMID: 21873211.
Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 71(15):5194-203, 2011. e-Pub 2011. PMID: 21670081.
Li J, Khavandgar Z, Lin SH, Murshed M. Lithium chloride attenuates BMP-2 signalling and inhibits osteogenic differentiation through a novel WNT/GSK3- independent mechanism. Bone 48:321-331, 2011. e-Pub 2011.
Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 102(11):812-827, 2010. e-Pub 2010. PMID: 20484106.
Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res 70(11):4580-4589, 2010. e-Pub 2010. PMID: 20484040.
Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Lin SH, Bast RC, Liu J. Human stanniocalcin 1 is a novel transforming oncogene in ovarian cancer. JNCI 102:812-827, 2010. e-Pub 2010.
Chuang C, Lin SH, Huang F, Pan J, Josic D, L-Y AY. Acetylation of RNA Processing Proteins and Cell Cylce Proteins in Mitosis. Journal of Proteome Research 3:4554-4564, 2010. e-Pub 2010.
Bawa-Khalfe T, Cheng T, Lin SH, Ittmann MM, and Yeh ET. SENP1 TRAMP SUMO-specific protease 1 induces prostate intraepithelial neoplasia through multiple mechanisms. J Biol Chem 285:25859-25866, 2010. e-Pub 2010.
Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, and Lin SH. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer 16:3875-3886, 2010. e-Pub 2010.
W-B T, Chung YM, Zou Y, S-H P, Xu Z, Nakayama K, Lin SH, and Hu MC. Inhibition of FOXO3 tumor suppressor function by BetaTrCP1 through ubiquitin-mediated degradation in a tumor mouse model. PLoS One 5:e11171, 2010. e-Pub 2010.
Wu CF, Wang R, Liang Q, Liang J, Li W, Jung SY, Qin J, Lin SH, Kuang J. Dissecting the M phase-specific phosphorylation of serine-proline or threonin-proline motifs. Mol Biol Cell 21:1470-1481, 2010. e-Pub 2010.
S-M T, Lin SH, Podoloff DA, Logothetis CJ. Multimodality Therapy: Bone-Targeted Radioisotope Therapy of Prostate Cancer. Clin Adv Hematol Oncol 8:341-351, 2010. e-Pub 2010.
Lee YC, C-F H, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, L-y Y, Gallick GE, and Lin SH. The Src Family Kinase/Abl Inhibitor Dasatinib Suppresses Proliferation and Enhances Differentiation of Osteoblasts. Oncogene 29:3196-3207, 2010. e-Pub 2010.
Y-C L, C-J C, Huang M, Bilen MA, Ye X, Navone NM, Chu K, H-H K, L-y Y, Wang Z, Lin SH. Androgen Depletion Upregulates Cadherin-11 Expression in Prostate Cancer. J. Path 221:68-76, 2010. e-Pub 2010.
Zhou X, Pan S, Sun L, Corvera L, Lin SH, Kuang J. The CHMP4b and Src docking sites in the Bro1 domain are autoinhibited in the native state of Alix. Biochem J 418:277-284, 2009. e-Pub 2009.
Zhang S, Wang J, Bilen MA, Lin SH, Stupp S, Satcher RL. Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clinical & Experimental Metastasis 26:993-1004, 2009. e-Pub 2009.
Zou' Y, W-B T, C-J C, Hsu C, C-H C, P-C L, Lin SH, M C-T AH. Forkhead box transcription factor FOX03a suppresses estrogen-dependent breast cancer cell survival and tumorigenesis. Breast Cancer Research 10(1):R21, 2008. e-Pub 2008.
Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27:596-603, 2008. e-Pub 2008.
Tu, S-M, Lin SH. Current trails using agents that target bone metastatsis in prostate cancer. Cancer J 14:35-39, 2008. e-Pub 2008.
Logothetis, CJ, Navone, NM, and Lin SH. Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer. Clinical Cancer Res 14:1599-1602, 2008. e-Pub 2008.
Garcia C, Aranda J, Arnold E, Thebault S, Macotela Y, Lopez-Casillas F, Mendoza V, Lin SH, Martinez de la Escalera G, and Clapp C. Vasoinhibins prevent diabetic retinopathy associated retinal vasopermeability increase via protein phosphatase 2A-dependent eNOs inactivation. J. Clin. Invest 118:2291-2300, 2008. e-Pub 2008.
Zhou X, Pan S, Sun L, Corvera J, Lin SH, Kuang J. The HIV-1 p6/EIAV p9 docking site in Alix is autoinhibited as conformation-sensitive anti-Alix monoclonal antibody. Biochem. J 414:215-220, 2008. e-Pub 2008.
Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest 118(8):2697-2710, 2008. e-Pub 2008.
Lira C, Chu K, Y-C L, Hu M, Lin SH. Expression of the extracellular domain of OB-cadherin as an Fc fusion protein using bicistronic retroviral expression vector. Protein Expression and Purification 61:220-226, 2008. e-Pub 2008.
Lin SH, Y-C L, Choueiri MB, Wen S, Mathew P, X-C Y, K-A D, Navone NM, Kim J, S-M T, L-Y Y, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin. Cancer Res 14:3729-3736, 2008. e-Pub 2008.
Lin SH, C-J C, Y-C L, W-W T, Kim J, Pasqualini R, Arap W, Navone NM, S-M T, Hu M, Y-Y Y, and Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27:5195-5203, 2008. e-Pub 2008.
Chu K, C-J C, Ye X, Y-C L, Zurita AJ, D-T C, L-Y Y, Zhang S, Yeh ET, C-T HM, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 6:1259-1267, 2008. e-Pub 2008.
Pan S, Wang R, Zhou X, Kloc M, Corvera J, Koomen J, Kobayashi R, Richrad Sifers R, Gallick GE, Lin SH, Kuang J. Extracellular Alix regulates integrin-mediated cell adhesions and extracellular matrix assembly. EMBO J 27:2077-2090, 2008. e-Pub 2008.
Y-C L, Block G, Chen H, Folch-Puy E, Foronjy R, Jalili R, Jendresen CB, Kimura M, Kraft E Lindemose S, Lu J, McLain T, Nutt L, Ramon-Garcia S, Smith J, Spivak A, Wang ML, Zanic M, Lin SH. One-step isolation of plasma membrane proteins using magnetic beads with immobolized concanavalin A. Protein Expression and Purification (This paper was completed by participants of 2008 Cold Spring Harbor Laboratory, Protein Purification and Characterization course) 62:223-229, 2008. e-Pub 2008.
Mathew P, Thall PF, Wen S, Bucana C, Fidler IJ, Jones D, Horne E, Oh WK, Morris MJ, Lin SH, Logothetis CJ. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leucocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Brit. J. Cancer 99:1426-1432, 2008. e-Pub 2008.
C-J C, X-C Y, Vakar-Lopez F, Kim J, S-M T, D-T C, Navone NM, L-Y Y, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5:675-684, 2007. e-Pub 2007.
S-H L, Kunz J, Lin SH, L-Y Y. 16-kDa prolactin inhibits endothelial cell migration by downregulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Research 67:11045-11053, 2007. e-Pub 2007.
Ye X C, Choueiri M, S-M T, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Frontier in Biosci 12:3273-86, 2007. e-Pub 2007.
D-T C, Chen JJ, Cheng G, Lin SH, Soong SJ. A two-stage binomial test approach of gene identification in oligonucleotide arrays. J. Biopharmaceutical Statistics 17:903-918, 2007. e-Pub 2007.
Chen N, X-C Y, Chu K, Navone NM, Sage EH, L-Y Y, Logothetis C, Lin SH. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67:6544-6548, 2007. e-Pub 2007.
Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 25:601-9, 2006. e-Pub 2006. PMID: 17160554.
Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107:497-505, 2006. e-Pub 2006. PMID: 16795067.
Nishino M, Kurasawa Y, Evans R, Lin SH, Brinkley W, L-Y Y. NudC is required for Plk1 targeting to the kinetochore and chromosome congression. Current Biology 16(14):1414-21, 2006. e-Pub 2006.
Nagaishi T, Pao L, Lin SH, Lijima H, Kaser A, S-W Q, Chen Z, Clickman J, S-M N, Nakajima A, Neel B G, Blumberg R S. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity 25(5):769-81, 2006. e-Pub 2006.
Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23(31):7904-10, 2005. e-Pub 2005. PMID: 16258090.
Liang AK, Liu J, Mao SA, Siu VS, Lee YC, Lin SH. Expression of recombinant MDA-BF-1 with a kinase recognition site and a 7-histidine tag for receptor binding and purification. Protein Expr Purif 44(1):58-64, 2005. e-Pub 2005. PMID: 15914029.
Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY, Tsai MJ. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65(17):7976-83, 2005. e-Pub 2005. PMID: 16140970.
Lee SH, Nishino M, Mazumdar T, Garcia GE, Galfione M, Lee FL, Lee CL, Liang A, Kim J, Feng L, Eissa NT, Lin SH, Yu-Lee LY. 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway. Cancer Res 65(17):7984-92, 2005. e-Pub 2005. PMID: 16140971.
Najjar SM, Yang Y, Fernstrom MA, Lee SJ, Deangelis AM, Rjaily GA, Al-Share QY, Dai T, Miller TA, Ratnam S, Ruch RJ, Smith S, Lin SH, Beauchemin N, Oyarce AM. Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab 2(1):43-53, 2005. e-Pub 2005. PMID: 16054098.
Tu, S-M, Kim, J, Pagliaro, LC, Vakar-Lopez, F, Wong, FC, Wen, S, General, R, Podoloff, DA, Lin SH, Logothetis, CJ. Strontium-89 combined with chemotherapy does not compromise subsequent therapy in selected patients with androgen-independent prostate cancer. J. Clin. Oncol 23:7904-7910, 2005. e-Pub 2005.
Gonzalez C, Corbacho AM, Eiserich JP, Garcia C, Lopez-Barrera F, Morales-Tlalpan V, Barajas-Espinosa A, Diaz-Munoz M, Rubio R, Lin SH, Martinez de la Escalera G, Clapp C. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145(12):5714-22, 2004. e-Pub 2004. PMID: 15358675.
Abou-Rjaily GA, Lee SJ, May D, Al-Share QY, Deangelis AM, Ruch RJ, Neumaier M, Kalthoff H, Lin SH, Najjar SM. CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation. J Clin Invest 114(7):944-52, 2004. e-Pub 2004. PMID: 15467833.
Britt DE, Yang DF, Yang DQ, Flanagan D, Callanan H, Lim YP, Lin SH, Hixson DC. Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells. Exp Cell Res 300(1):134-48, 2004. e-Pub 2004. PMID: 15383321.
Comegys MM, Lin SH, Rand D, Britt D, Flanagan D, Callanan H, Brilliant K, Hixson DC. Two variable regions in carcinoembryonic antigen-related cell adhesion molecule1 N-terminal domains located in or next to monoclonal antibody and adhesion epitopes show evidence of recombination in rat but not in human. J Biol Chem 279(33):35063-78, 2004. e-Pub 2004. PMID: 15184366.
Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203(2):688-95, 2004. e-Pub 2004. PMID: 15141384.
Phan D, Cheng CJ, Galfione M, Vakar-Lopez F, Tunstead J, Thompson NE, Burgess RR, Najjar SM, Yu-Lee LY, Lin SH. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Res 64(9):3072-8, 2004. e-Pub 2004. PMID: 15126343.
Lin SH, Nishino M, Luo W, Aumais JP, Galfione M, Kuang J, Yu-Lee LY. Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein. Oncogene 23(14):2499-506, 2004. e-Pub 2004. PMID: 14676831.
Chen DT, Lin SH, Soong SJ. Gene selection for oligonucleotide array: an approach using PM probe level data. Bioinformatics 20(6):854-62, 2004. e-Pub 2004. PMID: 14752002.
Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 95(15):1174-5; author reply 1175, 2003. e-Pub 2003. PMID: 12902452.
Aumais JP, Williams SN, Luo W, Nishino M, Caldwell KA, Caldwell GA, Lin SH, Yu-Lee LY. Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis. J Cell Sci 116(Pt 10):1991-2003, 2003. e-Pub 2003. PMID: 12679384.
Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C, Yu-Lee LY, Lin SH. Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. Protein Expr Purif 28(2):252-8, 2003. e-Pub 2003. PMID: 12699689.
Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63(2):386-93, 2003. e-Pub 2003. PMID: 12543792.
Wu Y, Pan S, Luo W, Lin SH, Kuang J. Hp95 promotes anoikis and inhibits tumorigenicity of HeLa cells. Oncogene 21(44):6801-8, 2002. e-Pub 2002. PMID: 12360406.
Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem 277(38):35696-702, 2002. e-Pub 2002. PMID: 12122002.
Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anticancer Drugs 13(7):743-9, 2002. e-Pub 2002. PMID: 12187331.
Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 168(1):51-5, 2002. e-Pub 2002. PMID: 12050491.
Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 2002. e-Pub 2002. PMID: 12173328.
Chua SS, Ma ZQ, Gong L, Lin SH, DeMayo FJ, Tsai SY. Ectopic expression of FGF-3 results in abnormal prostate and Wolffian duct development. Oncogene 21(12):1899-908, 2002. e-Pub 2002. PMID: 11896623.
Aumais JP, Tunstead JR, McNeil RS, Schaar BT, McConnell SK, Lin SH, Clark GD, Yu-Lee LY. NudC associates with Lis1 and the dynein motor at the leading pole of neurons. J Neurosci 21(24):RC187, 2001. e-Pub 2001. PMID: 11734602.
Phan D, Sui X, Chen DT, Najjar SM, Jenster G, Lin SH. Androgen regulation of the cell-cell adhesion molecule-1 (Ceacam1) gene. Mol Cell Endocrinol 184(1-2):115-23, 2001. e-Pub 2001. PMID: 11694347.
Estrera VT, Chen DT, Luo W, Hixson DC, Lin SH. Signal transduction by the CEACAM1 tumor suppressor. Phosphorylation of serine 503 is required for growth-inhibitory activity. J Biol Chem 276(18):15547-53, 2001. e-Pub 2001. PMID: 11278391.
Han E, Phan D, Lo P, Poy MN, Behringer R, Najjar SM, Lin SH. Differences in tissue-specific and embryonic expression of mouse Ceacam1 and Ceacam2 genes. Biochem J 355(Pt 2):417-23, 2001. e-Pub 2001. PMID: 11284729.
Phan D, Han E, Birrell G, Bonnal S, Duggan L, Esumi N, Gutstein H, Li R, Lopato S, Manogaran A, Pollak ES, Ray A, Reddi PP, Reichert AS, Struffi P, Tiscornia G, Ximenez-Fyvie LA, Zhang H, Lin SH. Purification and characterization of human cell--cell adhesion molecule 1 (C-CAM1) expressed in insect cells. Protein Expr Purif 21(2):343-51, 2001. e-Pub 2001. PMID: 11237697.
Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res 61(1):138-44, 2001. e-Pub 2001. PMID: 11196151.
Wang L, Lin SH, Wu WG, Kemp BL, Walsh GL, Hong WK, Mao L. C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers. Clin Cancer Res 6(8):2988-93, 2000. e-Pub 2000. PMID: 10955775.
Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, Grunert F, Hammarstrom S, Holmes KV, Karlsson A, Kuroki M, Lin SH, Lucka L, Najjar SM, Neumaier M, Obrink B, Shively JE, Skubitz KM, Stanners CP, Thomas P, Thompson JA, Virji M, von Kleist S, Wagener C, Watt S, Zimmermann W. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 252(2):243-9, 1999. e-Pub 1999. PMID: 11501563.
Estrera VT, Luo W, Phan D, Earley K, Hixson DC, Lin SH. The cytoplasmic domain of C-CAM1 tumor suppressor is necessary and sufficient for suppressing the tumorigenicity of prostate cancer cells. Biochem Biophys Res Commun 263(3):797-803, 1999. e-Pub 1999. PMID: 10512760.
Pu YS, Luo W, Lu HH, Greenberg NM, Lin SH, Gingrich JR. Differential expression of C-CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model. J Urol 162(3 Pt 1):892-6, 1999. e-Pub 1999. PMID: 10458403.
Hsieh JT, Earley K, Pong RC, Wang Y, Van NT, Lin SH. Structural analysis of the C-CAM1 molecule for its tumor suppression function in human prostate cancer. Prostate 41(1):31-8, 1999. e-Pub 1999. PMID: 10440873.
Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, Lin SH. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther 6(4):313-21, 1999. e-Pub 1999. PMID: 10419049.
Makarovskiy AN, Pu YS, Lo P, Earley K, Paglia M, Hixson DC, Lin SH. Expression and androgen regulation of C-CAM cell adhesion molecule isoforms in rat dorsal and ventral prostate. Oncogene 18(21):3252-60, 1999. e-Pub 1999. PMID: 10359531.
Comegys MM, Carreiro MP, Brown JF, Mazzacua A, Flanagan DL, Makarovskiy A, Lin SH, Hixson DC. C-CAM1 expression: differential effects on morphology, differentiation state and suppression of human PC-3 prostate carcinoma cells. Oncogene 18(21):3261-76, 1999. e-Pub 1999. PMID: 10359532.
Lin SH, Pu YS, Luo W, Wang Y, Logothetis CJ. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res 19(1A):337-40, 1999. e-Pub 1999. PMID: 10226564.
Mannion BA, Kolesnikova TV, Lin SH, Wang S, Thompson NL, Hemler ME. The light chain of CD98 is identified as E16/TA1 protein. J Biol Chem 273(50):33127-9, 1998. e-Pub 1998. PMID: 9837878.
Su LK, Wang SC, Qi Y, Luo W, Hung MC, Lin SH. Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. Oncogene 17(18):2377-81, 1998. e-Pub 1998. PMID: 9811469.
Chen ME, Lin SH, Chung LW, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 273(28):17618-25, 1998. e-Pub 1998. PMID: 9651357.
Lin SH, Cheng H, Earley K, Luo W, Chou J. Demonstration of adhesion activity of the soluble Ig-domain protein C-CAM4 by attachment to the plasma membrane. Biochem Biophys Res Commun 245(2):472-7, 1998. e-Pub 1998. PMID: 9571177.
Luo W, Earley K, Tantingco V, Hixson DC, Liang TC, Lin SH. Association of an 80 kDa protein with C-CAM1 cytoplasmic domain correlates with C-CAM1-mediated growth inhibition. Oncogene 16(9):1141-7, 1998. e-Pub 1998. PMID: 9528856.
Luo W, Lin SH. Generation of moderate amounts of polyclonal antibodies in mice. Biotechniques 23(4):630-2, 1997. e-Pub 1997. PMID: 9343678.
Pisters LL, el-Naggar AK, Luo W, Malpica A, Lin SH. C-met proto-oncogene expression in benign and malignant human renal tissues. J Urol 158(3 Pt 1):724-8, 1997. e-Pub 1997. PMID: 9258068.
Wang SC, Lin SH, Su LK, Hung MC. Changes in BRCA2 expression during progression of the cell cycle. Biochem Biophys Res Commun 234(1):247-51, 1997. e-Pub 1997. PMID: 9168997.
Luo W, Wood CG, Earley K, Hung MC, Lin SH. Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. Oncogene 14(14):1697-704, 1997. e-Pub 1997. PMID: 9135071.
Kleinerman DI, Dinney CP, Zhang WW, Lin SH, Van NT, Hsieh JT. Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. Cancer Res 56(15):3431-5, 1996. e-Pub 1996. PMID: 8758907.
Luo W, Liang TC, Li JM, Hsieh JT, Lin SH. A universal tag for recombinant proteins. Arch Biochem Biophys 329(2):215-20, 1996. e-Pub 1996. PMID: 8638954.
Earley K, Luo W, Qiu Y, Thompson NL, Chou J, Hixson DC, Lin SH. Identification of a new isoform of cell-cell adhesion molecule 105 (C-CAM), C-CAM4: a secretory protein with only one Ig domain. Biochem J 315 ( Pt 3):799-806, 1996. e-Pub 1996. PMID: 8645160.
Chapman L, Sang J, Lin SH, Hixson DC, Thompson NL. Cloning of cDNAs from a mammalian expression library by a direct selection-amplification method. Mol Biotechnol 5(2):77-83, 1996. e-Pub 1996. PMID: 8734421.
Chen X, Earley K, Luo W, Lin SH, Schilling WP. Functional expression of a human thrombin receptor in Sf9 insect cells: evidence for an active tethered ligand. Biochem J 314 ( Pt 2):603-11, 1996. e-Pub 1996. PMID: 8670076.
Liang, TC, Luo, W, Hsieh, JT, Lin SH. Characterization of a monoclonal antibody revealed a novel binding epitope. Archiv. Biochem. Biophys 329:208-214, 1996. e-Pub 1996.
Lin SH, Luo W, Earley K, Cheung P, Hixson DC. Structure and function of C-CAM1: effects of the cytoplasmic domain on cell aggregation. Biochem J 311 ( Pt 1):239-45, 1995. e-Pub 1995. PMID: 7575460.
Kleinerman DI, Zhang WW, Lin SH, Nguyen TV, von Eschenbach AC, Hsieh JT. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res 55(13):2831-6, 1995. e-Pub 1995. PMID: 7796410.
Kleinerman DI, Troncoso P, Lin SH, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh JT. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 55(6):1215-20, 1995. e-Pub 1995. PMID: 7533659.
Baum O, Reutter W, Flanagan D, Callanan H, Lim YP, Lin SH, Hixson DC. Anti-peptide sera against cell-CAM 105 determine high molecular-mass variants of the long isoform in rat hepatocytes. Eur J Biochem 228(2):316-22, 1995. e-Pub 1995. PMID: 7705345.
Hsieh JT, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin SH. Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 55(1):190-7, 1995. e-Pub 1995. PMID: 7805032.
Hsieh JT, Lin SH. Androgen regulation of cell adhesion molecule gene expression in rat prostate during organ degeneration. C-CAM belongs to a class of androgen-repressed genes associated with enriched stem/amplifying cell population after prolonged castration. J Biol Chem 269(5):3711-6, 1994. e-Pub 1994. PMID: 8106416.
Thompson NL, Lin SH, Panzica MA, Hixson DC. Cell CAM 105 isoform RNA expression is differentially regulated during rat liver regeneration and carcinogenesis. Pathobiology 62(4):209-20, 1994. e-Pub 1994. PMID: 7734064.
Cheung PH, Luo W, Qiu Y, Zhang X, Earley K, Millirons P, Lin SH. Structure and function of C-CAM1. The first immunoglobulin domain is required for intercellular adhesion. J Biol Chem 268(32):24303-10, 1993. e-Pub 1993. PMID: 8226979.
Lim YP, Callanan H, Lin SH, Thompson NL, Hixson DC. Preparative mini-slab gel continuous elution electrophoresis: application for the separation of two isoforms of rat hepatocyte cell adhesion molecule, cell-CAM 105, and its associated proteins. Anal Biochem 214(1):156-64, 1993. e-Pub 1993. PMID: 8250219.
Cheung PH, Culic O, Qiu Y, Earley K, Thompson N, Hixson DC, Lin SH. The cytoplasmic domain of C-CAM is required for C-CAM-mediated adhesion function: studies of a C-CAM transcript containing an unspliced intron. Biochem J 295 ( Pt 2):427-35, 1993. e-Pub 1993. PMID: 8240240.
Cheung PH, Earley K, Liang TC, Lin SH. Conformation dependence of antipeptide antibodies: characterization of cell-CAM105 isoform-specific antipeptide antibodies using proteins expressed in insect cells with baculoviral vectors. Arch Biochem Biophys 305(2):563-9, 1993. e-Pub 1993. PMID: 8373195.
Thompson NL, Panzica MA, Hull G, Lin SH, Curran TR, Gruppuso PA, Baum O, Reutter W, Hixson DC. Spatio-temporal expression of two cell-cell adhesion molecule 105 isoforms during liver development. Cell Growth Differ 4:257-68, 1993. e-Pub 1993. PMID: 8494790.
Cheung PH, Thompson NL, Earley K, Culic O, Hixson D, Lin SH. Cell-CAM105 isoforms with different adhesion functions are coexpressed in adult rat tissues and during liver development. J Biol Chem 268(9):6139-46, 1993. e-Pub 1993. PMID: 8454589.
Culic O, Huang QH, Flanagan D, Hixson D, Lin SH. Molecular cloning and expression of a new rat liver cell-CAM105 isoform. Differential phosphorylation of isoforms. Biochem J 285 ( Pt 1):47-53, 1992. e-Pub 1992. PMID: 1637321.
Sabolic I, Culic O, Lin SH, Brown D. Localization of ecto-ATPase in rat kidney and isolated renal cortical membrane vesicles. Am J Physiol 262(2 Pt 2):F217-28, 1992. e-Pub 1992. PMID: 1311523.
Lin SH, Culic O, Flanagan D, Hixson DC. Immunochemical characterization of two isoforms of rat liver ecto-ATPase that show an immunological and structural identity with a glycoprotein cell-adhesion molecule with Mr 105,000. Biochem J 278 ( Pt 1):155-61, 1991. e-Pub 1991. PMID: 1831973.
Lin SH. Localization of the ecto-ATPase (ecto-nucleotidase) in the rat hepatocyte plasma membrane. Implications for the functions of the ecto-ATPase. J Biol Chem 264(24):14403-7, 1989. e-Pub 1989. PMID: 2527234.
Lin SH, Guidotti G. Cloning and expression of a cDNA coding for a rat liver plasma membrane ecto-ATPase. The primary structure of the ecto-ATPase is similar to that of the human biliary glycoprotein I. J Biol Chem 264(24):14408-14, 1989. e-Pub 1989.
Lin SH, Russell WE. Two Ca2+-dependent ATPases in rat liver plasma membrane. The previously purified (Ca2+-Mg2+)-ATPase is not a Ca2+-pump but an ecto-ATPase. J Biol Chem 263(25):12253-8, 1988. e-Pub 1988.
Lin SH. The rat liver plasma membrane high affinity (Ca2+-Mg2+)-ATPase is not a calcium pump. Comparison with ATP-dependent calcium transporter. J Biol Chem 260(20):10976-80, 1985. e-Pub 1985.
Lin SH. Novel ATP-dependent calcium transport component from rat liver plasma membranes. The transporter and the previously reported (Ca2+-Mg2+)-ATPase are different proteins. J Biol Chem 260(13):7850-6, 1985. e-Pub 1985.
Lin SH, Fain JN. Purification of (Ca2+-Mg2+)-ATPase from rat liver plasma membranes. J Biol Chem 259(5):3016-20, 1984. e-Pub 1984.
Lin SH, Wallace MA, Fain JN. Regulation of Ca2+-Mg2+-ATPase activity in hepatocyte plasma membranes by vasopressin and phenylephrine. Endocrinology 113(6):2268-75, 1983. e-Pub 1983.
Litosch I, Lin SH, Fain JN. Rapid changes in hepatocyte phosphoinositides induced by vasopressin. J Biol Chem 258(22):13727-32, 1983. e-Pub 1983.
Fain JN, Lin SH, Litosch I, Wallace M. Hormonal regulation of phosphatidylinositol breakdown. Life Sci 32(18):2055-67, 1983. e-Pub 1983.
Lin SH, Fain JN. Vasopressin and epinephrine stimulation of phosphatidylinositol breakdown in the plasma membrane of rat hepatocytes. Life Sci 29(18):1905-12, 1981. e-Pub 1981.
Huang FL, Huang CJ, Lin SH, Lo TB, Papkoff H. Isolation and characterization of gonadotropin isohormones from the pituitary gland of pike eel (Muraenesox cinereus). Int J Pept Protein Res 18(1):69-78, 1981. e-Pub 1981.
Satcher R, Bamidele O, Lin P, Lin SH, Moon B, Hernandez M, Lewis V, Chilton J. Racial disparities in survival outcomes of prostate cancer patients after surgery for bone metastases. Journal of Cancer Therapy.

Invited Articles

S-H L, Guidotti G. Purification and membrane proteins. In Methods in Enzymology. Guide to Protein Purification. Burgess, R. and Deutscher M. Editors 463:619-629, 2009. e-Pub 2009.
Tu SM, Lin SH. Clinical aspects of bone metastases in prostate cancer. In the Biology of Bone Metastases Keller E, and Chung L., Editors, Kluwer Academin Publishers, Boston, MA 118:23-46, 2004. e-Pub 2004.
Lin SH, Pu YS. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer. Semin Oncol 26(2):227-33, 1999. e-Pub 1999.
S-H L. CAM as target for gene therapy. Cancer Research Therapy and Control 7:247-252, 1998. e-Pub 1998.
Beauchemin, Lin N, S-H. Role of C-CAM as a tumor suppressor. Cell adhesion and communication mediated by the CEA family: basic and clinical perspectives 5:155-175, 1998. e-Pub 1998.
Lin SH. Liver plasma membrane ecto-ATPase. Purification, localization, cloning, and functions. Ann N Y Acad Sci 603:394-400, 1990. e-Pub 1990.

Review Articles

Lin SC, Yu-Lee LY, Lin SH. Osteoblastic Factors in Prostate Cancer Bone Metastasis. Curr Osteoporos Rep 16(6):642-647, 2018. e-Pub 2018. PMID: 30203251.
Chahoud J, Zhang M, Shah A, Lin SH, Pisters LL, Tu SM. Managing seminomatous and nonseminomatous germ cell tumors. Curr Opin Oncol 30(3):181-188, 2018. e-Pub 2018. PMID: 29538040.
Farach-Carson MC, Lin SH, Nalty T, Satcher RL. Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?. Front Oncol 7:163, 2017. e-Pub 2017. PMID: 28824875.
Ortiz A, Lin SH. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum?. Recent Results Cancer Res 192:225-33, 2012. e-Pub 2012. PMID: 22307378.
Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. Cancer J 14(1):35-9, 2008. e-Pub 2008. PMID: 18303481.
Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1):21-8, 2005. e-Pub 2005. PMID: 15630412.
Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3(8):508-13, 2002. e-Pub 2002. PMID: 12147437.

Professional Educational Materials

Lee YC, Liu HC, Chuang C, Lin SH. Lectin-magnetic beads for plasma membrane isolation. Cold Spring Harbor Protocol: Cellular Fractionation, 2014.
Brocklehurst, K, Courey, AJ, Gul, S, Lin, S-H, Moritz, LR. Purification and analysis of proteins. Cold Spring Harbor Laboratory Press, 2004.
Marshak, D, Burgess, R, Kadonaga, J, Brennan, W, Lin, S-H. Protein purification and characterization, a course manual. Cold Spring Harbor Laboratory Press, 1996.

Abstracts

Satcher R, Pan T, Lee YC, Lin SC, Yu G, Lin SH. Increased expression of Cadherin 11 in bone-derived 786-O renal cell carcinoma cells, 2013. e-Pub 2013.
Lin SH, Kuang, J. RSK2 regulates prostate cancer cell proliferation through phosphorylation of Cdc25. Department of Defense 2011 IMPaCT Meeting, 2011. e-Pub 2011.
Sue-Hwa L, Logothetis C. Osteoblastic stimulatory activity in prostate cancer bone metastasis. Skeletal Complications of Malignancy, 2005. e-Pub 2005.
Sue-Hwa L, Logothetis C. The bone marrow proteome as a discovery platform to understand prostate cancer progression. Inter-Prostate SPORE Meeting, 2005. e-Pub 2005.
Satcher R, Pan T, Y-C L, S-C L, Yu G, S-W L. Increased expression of Cadherin 11 in bone-derived 786-O renal cell carcinoma cells. Musculoskeletal Tumor Society Annual Meeting, 2004. e-Pub 2004.
Gonzalez, M Corbacho CA, Eiserich JP, Lin S, la Escalera GMD, Clapp C. 16K Prolactin Inhibits VEGF-Induced Nitric Oxide Production in Endothelial Cells. Endocrine Society Annual Meeting, 2003. e-Pub 2003.
Lin, Sue-Hwa, Kim J, Tunstead J, Chen D, Luo W, Earley K, Yu-Lee L. Effectors of 16-kDa Prolactin in Endothelial Cells. Endocrine Society Annual Meeting, 2003. e-Pub 2003.
Phan, D, Jenster, G, Najjar, S, Lin, S-H. Transcriptional regulation of C-CAM1 gene by androgen receptor. 10th International CEA workshop, 1999. e-Pub 1999.
Estrera, V, Luo, W, Phan, D, Lin, S-H. The cytoplasmic domain of C-CAM1 cell adhesion molecule in necessary and sufficient for suppressing the tumorigenicity of prostate cancer cells. 10th International CEA Workshop, 1999. e-Pub 1999.
Lin, S-H, Luo, W, Logothetis, C. Enhanced suppression of prostate tumor growth by combination of C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. 10th International CEA Workshop, 1999. e-Pub 1999.
Arlinghaus, R, Liu, J, Wang, Y, Hawk, N, Wu, Y, Sun, T, Lin, S-H, Luo, W, Guo, JQ, Talpaz, M, Estrov, Z, Liang, J. Bcr and Bcr-Abl interaction: Cis and Trans modes of tyrosine kinase inhibition. American Society of Hematology Annual Meeting, 1999. e-Pub 1999.

Book Chapters

Holmes, KV, Dveksler, G, Gagneten, S, Yeager, C, Lin, S-H, Beauchemin, N, Look, AT, Ashmun, R, Dieffenbach, C. Coronavirus receptor specificity. In: Coronaviruses: Molecular Biology and Pathogenesis. In: Advances in Experimental Medicine and Biology. Plenum Publishing Co. Ltd, 261-6, 1993.
Lin, S-H, Culic, O. Studies on liver ecto-ATPase: A cell adhesion molecule of carcinoembryonic antigen family. In: SETS/CPPTS proceedings, BS1-7, 1992.
Cheung, P, Lin, S-H. Structure function study of liver adhesion molecule. In: cell-CAM105, 11-24, 1992.
S-H L. The high affinity Ca(Mg)-ATPase of rat liver plasma membrane hydrolyzes extracellular ATP. In: Cell Calcium metabolism: Physiology, biochemistry, pharmacology and clinical applications. Plenum Press, 13-19, 1989.
Fain, JN, Lin, S-H, Litosch, I, Wallace, MA. Relationship between vasopressin activation of rat hepatocyte glycogen phosphorylase, inhibition of Ca-Mg-ATPase and phosphoinositide breakdown. In: Inositol and Phosphoinositides. Humana Press, 255-274, 1985.
Fain, JN, Wallace, MA, Lin, S-H, Litosch, I. Hormonal regulation of phosphoinositide metabolism in rat hepatocytes. In: Calcium in Biological Systems. Plenum Publishing Corp, 61-65, 1985.
Lin, S-H, Fain, JN. Ca-Mg-ATPase in rat hepatocyte plasma membranes, Inhibition by basopressin and purification of the enzyme. In: Epithelial calcium and phosphate transport: Molecular and cellular aspects. A.R. Liss, 25-30, 1984.
Fain, JN, Lin SH, Randazzo, P, Robinson, S, Wallace, MA. Hormonal regulation of glycogen phosphorylase in rat hepatocytes: Activation of phosphatidylinositol breakdown by vasopressin and alpha-catecholamines. In: Isolation, characterization and use of hepatocytes. Elsevier Publishing Co, 411-418, 1983.

Patents

S-H L, Luo W, and Logothetis C. C-CAM as an angiogenesis inhibitor. Patent Number: UTMDACC: UTSC:623US/10019197 (MDA99-042), SN 09/580,043, Patent no. 6,517,828.

Less

CV information above last modified July 22, 2026

Sue-Hwa Lin, Ph.D.

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Abstracts

Book Chapters

Patents

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Sue-Hwa Lin, Ph.D.

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Abstracts

Book Chapters

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson